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Abstract: Cases of PML should be evaluated according to predisposing factors, as these
subgroups differ by incidence rate, clinical course, and prognosis. The three most signiﬁcant
groups at risk of PML are patients with hematological malignancies mostly previously
treated with immunotherapies but also untreated, patients with HIV infection, and patients
using monoclonal antibody (mAb) treatments. Epidemiological data is scarce and partly
conﬂicting, but the distribution of the subgroups appears to have changed. While there is no
speciﬁc anti-JCPyV treatment, restoration of the immune function is the most effective
approach to PML treatment. Research is warranted to determine whether immune checkpoint
inhibitors could beneﬁt certain PML subgroups. There are no systematic national or inter-
national records of PML diagnoses or a risk stratiﬁcation algorithm, except for MS patients
receiving natalizumab (NTZ). These are needed to improve PML risk assessment and to
tailor better prevention strategies.
Keywords: progressive multifocal leukoencephalopathy, JC polyomavirus, monoclonal
antibodies, HIV, multiple sclerosis, disease modifying therapies
Introduction
Progressive multifocal leukoencephalopathy (PML) is an opportunistic viral infec-
tion of the central nervous system (CNS) ﬁrst described in 1958 by Åström and
colleagues.1 PML, named after its pathological features, is a progressive multi-
focal disease of white matter, which can now be thought of as the classical form of
PML. The disease is caused by the JC polyomavirus (JCPyV). The prerequisite for
PML is profound suppression of cell-mediated immunity, whether associated with
diseases, such as HIV or lymphoproliferative malignancies, or treatment with
immunosuppressive or immunomodulatory therapies (multiple sclerosis or rheu-
matoid arthritis) or both (systemic lupus erythematosus). Epidemiological data for
different PML subgroups is scarce and partly conﬂicting because there are no
systematic national or international records of PML diagnoses and only a few
population-based studies of PML incidence. During the 1980’s and 1990’s with
the emergence of HIV in humans, PML was the most important opportunistic
infection of the CNS in these patients and most PML cases occurred in this group.
In recent times, PML has been increasingly diagnosed in patients treated with
biological therapies such as mAbs which deplete lymphocytes or impede leuko-
cytes trafﬁcking into the CNS. Interest in PML increased in 2005 when its
association with the multiple sclerosis (MS) drug natalizumab (NTZ) was
discovered2 and MS patients have become an important population at possible
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risk of PML.3 NTZ provides a good example how the
risk-beneﬁt proﬁle must be determined at the individual
level. PML risk also affects certain other MS therapies to
a smaller degree. Other mAbs, as well as chemotherapy
needed to treat patients with malignant diseases or after
solid organ (SOT) or hematopoietic stem cell transplanta-
tion (HSCT) are also associated with an increased risk of
PML.4
PML diagnosis is based upon distinguishing neurological
features, characteristic changes in brain magnetic resonance
imaging (MRI), and the presence of JCPyV DNA in cere-
brospinal ﬂuid (CSF). Currently reconstitution of the
immune system gives the best prognosis for this condition.
As the etiology of PML has changed, so have its diag-
nosis and management. The nature of immunosuppression
underlying PML determines the prognosis, treatment, and the
risk of PML immune reconstruction inﬂammatory syndrome
(PML-IRIS). Detection of PML at an early stage, when the
disease is asymptomatic and restricted, is associated with
a better outcome and higher survival rate.5,6
JCPyV Infection
JCPyV is a member of the Polyomaviridae family and has a 5
kb double-stranded circular DNA genome. The initial route
of infection is thought to be ingestion or respiratory inhala-
tion. The virus is then transported into kidney epithelial cells,
bone marrow and spleen, where it establishes life-long per-
sistence. JCPyValso persists in the lymphocytes.
Primary asymptomatic infection usually occurs in child-
hood, but adult infections are also possible. Primary infection
is caused by the so called “archetype” virus, where the non-
coding control region (NCCR) has a certain block structure.
Occasionally, in immunosuppressed but also in healthy indi-
viduals, asymptomatic reactivation of JCPyV may take
place, and the virus is excreted in the urine. Upon active
viral replication in immunosuppressed individuals rearrange-
ments in the viral genome may emerge, which mainly affect
the NCCR but occasionally also the VP1 viral capsid protein.
The archetype virus does not replicate efﬁciently in the brain,
whereas the so called neurotropic variants harboring NCCR
rearrangements can actively replicate in glial cells.Mutations
in VP1 may additionally favor virus tropism for alternative
cell populations, increasing the risk of PML. Mutations
within the large T antigen and agnoprotein genes have also
been reported in both PML7,8 and non-PML patients.9
Although most primary infections take place in child-
hood, the development of PML in childhood is extremely
uncommon. JCPyV seroprevalence increases with age and
reaches 90% in adults with occasional JCPyV shedding in
urine within 19–27% of individuals.10 Each year 3% or
less of the seronegative population becomes infected.11
The rarity of PML despite the widespread prevalence of
JCPyV implies robust barriers to the development of the
disease. Cell-mediated immunity is crucial for controlling
JCPyV, as reﬂected by the high rates of the disease in
advanced HIV infection, especially when the CD4+ lym-
phocyte count is below 100 cells/mm3. However, B cells
and CD34+ progenitors also play roles in the pathophy-
siology, acting as viral reservoirs, and as a vector for viral
dissemination in the CNS.12 B-cell depletion disrupts
CD4- and CD8-positive T-cells homeostasis. Plasma cells
regulate inﬂammatory T-cells activity via the immuno-
checkpoin pathways, thereby protecting the brain from
excessive immune-mediated damage during active
JCPyV infection.13 The role of anti-JCPyV antibodies is
not yet completely understood. As more than half of PML
patients are seropositive before the onset of PML, humoral
immune responses seem insufﬁcient to protect the patient
from developing PML. Altogether higher antibody levels
have been detected in patients before PML diagnosis as
compared to patients who did not develop PML.14 Increase
in anti-JCPyVantibody levels in NTZ treated patients prior
to or coinciding with PML diagnosis has been suggested in
some studies,15,16 possibly associated with virus reactiva-
tion. Other studies report stable high anti-JCPyV antibody
levels prior to PML, although the authors considered the
possibility that an increase in antibody levels may have
been hidden by antibody assay saturation.17
PML is not the only disorder caused by JCPyV.
Nephropathy with or without PML has been observed in
renal allograft recipients.18 JCPyV can also infect menin-
geal and choroid plexus cells causing JCPyV meningitis
(JCVM).19 There are reported cases of granule cell neuro-
nopathy (JCVGCN) of the cerebellum.20 Fulminant JCPyV
encephalopathy (JCE), involving cortical pyramidal neu-
rons, is characterized by infection and lysis of cortical
gray matter.21 JCPyV has been found in the brain of other-
wise healthy individuals22 and therefore the presence of the
virus is insufﬁcient to make a diagnosis of PML.
Neuropathology
Pathologic features in PML include demyelination with
the presence of foamy macrophages, relative preservation
of axons, and astrogliosis, sometimes with atypical astro-
cytic nuclei and opale oligodendroglial nuclei. These oli-
godendroglial nuclei are ﬁlled with virus particles when
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viewed by electron microscopy, and the nuclei are consis-
tently positive in immunohistochemistry using the mono-
clonal antibody to JCPyV, and in JCPyV in-situ
hybridization (ISH). Neurons in the adjacent cortex can
also become infected by the virus. Neurons in the adjacent
cortex can also become infected by the virus.23
Epidemiology of PML
Population-based studies on PML epidemiology are scarce
and long-term overall incidence trends are largely unknown
(Table 1). Most papers report incidence in speciﬁc patient
populations because PML was rare among patients not
infected with HIV up to the mid-2000s,24 also the risk has
decreased among HIV-patients after introduction of highly
active antiretroviral therapy (HAART).25 A recent popula-
tion-based Swedish study reported that after two decades of
stable PML incidence of 0.026/100,000 person-years, the
incidence has increased to 0.11 in 2011–2013, apparently
related to the use of mAb therapies.26 Finnish population-
based registry study investigating the period 2004–2014
reported an overall lower PML incidence of 0.072/
100,000 person-years with no temporal incidence trend
despite the increasing use of mAbs at the national level.27
In the most recent study from southern Finland in
2004–2016, we reported a PML-incidence of 0.12/
100,000 person-years with no sign of increase.28 In this
study the data was obtained from clinical records and the
HIV Quality Registry. The discrepancy in incidence trends
may be explained by differences in national circumstances
and research methods. Nevertheless, they indicate that more
studies from different regions and with in-depth analysis of
PML causes are needed. Moreover, national PML surveil-
lance and recording protocols would be helpful.
Underlying Diseases
Hematologic and Oncologic Conditions
PML was originally described in untreated patients with
chronic lymphocytic leukemia (CLL) and Hodgkin’s
disease.1 Currently patients with malignancies are the
largest PML population,26,27 see Figure 1. PML can
still occur in untreated patients but is more commonly
associated with immunosuppressive or immunomodula-
tory treatments.29 Increased use of mAbs and HSCT
correlate with rising PML incidence among patients
with hematologic malignancies.30 Hematologic condi-
tions associated with PML include CLL, Hodgkin’s dis-
ease, non-Hodgkin’s lymphoma, acute myeloid leukemia,
acute lymphoblastic leukemia, Waldeström macroglobu-
linemia, multiple myeloma, polycythemia vera, and
mycosis fungoides.28,29,31 Major PML risk factors are
Table 1 Incidence Rate of PML in Different Populations
Population Period Country Incidence Rate Reference
General population 2004–2016 Southern
Finland
0.12 per 100,000 individuals per year 28
General population 2004–2014 Finland Annual incidence 0.072/100,000 person-years 27
General population 1988–2013 Sweden 0.026–0.11 per 100,000 individuals per year 26
AIDS patients 1996–2011 Spain 14.8/1000 patients/year in 1996 to 2.6 in 2005 and
0.8 in 2011
25
Heart and lung transplant recipients 1988–2008
1995–2008
1991–2010
US
Holland
1.24 per 1000 post-transplantation person-years 38
Non-Hodgkin disease patients receiving RTX 2000–2008 Italy 2.89 110
SLE patients 1998–2005 US 4 per 100,000 43
RA patients 1998–2005 US 0.4 per 100,000 43
Connective tissue diseases patients (other than
SLE and RA)
1998–2005 US 2 per 100,000 43
B-cell CLL patients 1987–1991 US 1.08 111
Hodgkin’s disease patients 1970–1984 Holland 0.46 112
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uncontrolled Hodgkin’s disease, treatment with purine
analogues, and treatments related to HSCT.32 The prog-
nosis is on the same level as in HIV-PML, but worse
than in PML associated with autoimmune disorders.26,27
HIV Infection
Previously HIV was the underlying condition in approxi-
mately 80% of PML cases33 but in addition to improving
survival, the HAART has reduced the incidence of HIV-
PML34 (Table 1). Indeed, HIV’s share as the predisposing
disease has been 16–31% in the recent Nordic studies
(Figure 1). The median survival time of HIV-PML patients
in Denmark increased from 0.4 years in 1995–1996 to 1.8
years in 1997–200635 and a recent study from Spain
reported a 1-year survival of 55% (79% when CD4+
count was >100 cells/mm3 at diagnosis) and a 50%
3-year survival.25 Similarly, the recent 1-year survival
rate of HIV-PML patients was 75% in Paris, France.36 In
the recent Swedish study, HIV-PML was correlated with
higher mortality compared to PML associated with auto-
immune disease or a malignancy26 whereas the recent
Finnish study reported similar survival in HIV-PML or
a malignancy (66% at 1 year), albeit poorer than in PML
associated with a connective tissue disorder.27 CD4+ lym-
phocyte counts of <200 cells/µl are a known PML risk
factor in HIV patients although patients with CD4+ counts
above that and/or receiving HAART may also be
affected.37
Organ Transplantations
PML is a known complication associated with bone marrow
transplants and SOT. The risk of PML among heart or lung
transplant recipients is comparable to the PML risk asso-
ciated with NTZ treatment for MS (Table 1).2,38 The most
important risk factor for PML is immunosuppressive medi-
cation to prevent graft rejection.38 Median time from trans-
plantation to onset of PML is 27 months in solid organ vs 11
months in bone marrow recipients. The fatality rate is high,
around 84%, and the 1-year survival rate is 56%.38
PML has been described in patients with either auto-
logous or allogenic stem cell transplantation.39,40 PML
risk is present due to invasive conditioning regimens and
prolonged immune suppression. Symptoms typically
develop more than 1 month after HSCT and have been
reported as late as several years post-transplantation. In the
transplantation population (both SOT and HSCT), PML is
mostly associated with ﬂudarabine and RTX therapy.41
42%
31%
21%
6%
Iacobaeus et al.
Malignancy HIV/AIDS
Autoimmune disease Previously healthy
60%17%
23%
0%
Sipilä et al.
Malignancy HIV/AIDS
Autoimmune disease Previously healthy
61%
16%
16%
7%
Kartau et al.
Malignancy HIV/AIDS
Autoimmune disease Previously healthy
Figure 1 The distributions of PML etiologies.
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Autoimmune Diseases (Other Than MS)
The number of PML cases connected to autoimmune dis-
ease has been increasing since 2006.42 PML is usually
ascribed to the drugs used to treat these diseases. The
incidence rates are shown in Table 1.
Of all rheumatologic conditions, systemic lupus erythe-
matosus (SLE) has the highest PML risk.43 Most SLE
patients who develop PML have been subjected to, or are
under immunosuppressant therapy. While the main cause
of PML in SLE patients is therapy-related, it is possible
that SLE may increase PML risk itself. A role of lympho-
penia has been suggested.44
Other PML associated rheumatic diseases are vasculitis,
most notably Wegener granulomatosis, poly- and dermato-
myositis, scleroderma and rheumatoid arthritis (RA). There
are reports of PML in patients with Sjögren syndrome and
sarcoidosis with no prior immunomodulatory therapy, but
with considerable lymphopenia.45 Rheumatological drugs
that may cause PML are rituximab, methotrexate, leﬂuno-
mide, and inﬂiximab.46 In the recent nationwide studies,
PML associated with an autoimmune disorder had a more
favorable prognosis than PML associated with HIV or
malignancy.26,27
Idiopathic Immune Deﬁciency Syndromes
PML has been described in patients with several types of
primary immunodeﬁciency disorders (PIDs). PIDs are rare
inherited disorders, characterized by a wide range of syn-
dromic or genetic defects, mostly with combined B and
T cell impairment. Idiopathic CD4+ T lymphocytopenia is
the most commonly reported PID behind PML.47 Many
PML cases are secondary to immunosuppressive treatments
such as prolonged steroid therapy, RTX, azathioprine, or
anti-TNF-α used to treat autoimmune, inﬂammatory, or
proliferative PID complications.48 According to a study of
11 PID-PML patients, all patients but one died after
a median of 8 months following PML diagnosis.48
PML in the Setting of Minimal or No
Immunodeﬁciency
Some cases of PML have been reported with less overt
immunodeﬁciency, such as chronic kidney and liver dis-
eases, type 2 diabetes mellitus, dementia.28,49 There is one
histologically proven PML case each concerning
a pregnant woman, and a woman prior to pregnancy with-
out any known underlying immunodeﬁciency.50,51 There is
no epidemiological data suggesting that pregnant MS
patients or healthy women have a higher incidence
of PML.
PML in the Setting of mAb Therapy and Other
Immunomodulating Drugs
Monoclonal antibody therapeutics have dramatically
improved the therapy of chronic inﬂammatory diseases
and cancers.52 Some mAbs repress the immune system
for long periods, and predispose the patient to opportunis-
tic infections. In addition to NTZ, other mAbs associated
with PML are efalizumab and RTX. Efalizumab was with-
drawn from the market in 2009 due to its association with
PML. The incidence of PML due to RTX treatment is
estimated to be 1 case per 32,000.4 There is an increased
risk of PML in patients with SLE (1 case per 4000 indi-
viduals) and RA (1 case per 25,000 individuals) treated
with rituximab (RTX).53 Many other mAbs have also been
reported as risk factors of PML (Table 2).54 Patients with
PML related to mAb treatment may have different clinical
picture compared to classic PML. Once PML is identiﬁed,
the mAb must be discontinued without delay and removed
by plasmapheresis.
In addition to mAb, numerous other drugs are asso-
ciated with PML (Table 2).54,55 These drugs have differ-
ences in the incidence rate of PML, the nature of the
underlying diseases being treated, and the time from start-
ing treatment to the development of PML.
Risk of PML is associated with several disease mod-
ifying therapies (DMTs) for MS (Table 3).56–60 The mode
of action of DMTs plays a role in causing PML.61 The best
studied DMT associated to PML is NTZ,61 which is
a mAb that inhibits the transmembrane leukocyte receptor
α-4 integrin. It prevents leukocyte adhesion to vessel walls
and subsequent migration across the blood–brain barrier,
resulting in immunosuppression within the CNS. The
more the CNS compartment is immunocompromised, the
greater the risk of PML. NTZ may also inhibit the reten-
tion of lymphocytes in bone marrow and spleen, thus
leading to an increase of JCPyV-infected peripheral leu-
kocytes and to a possible increase of the peripheral JCPyV
load.62 As of September 3, 2019 there have been 825
conﬁrmed PML cases (822 MS, 3 Crohn’s disease)
according to latest Tysabry Safety Update information.
The overall global incidence of PML in NTZ-treated
patients is 4.08 per 1000 patients (95% CI 3.80 to
4.36 per 1000 patients). The duration of NTZ dosing
prior to PML diagnosis ranged from 8 to 148 doses, and
the mean duration of NTZ dosing at time of PML
Dovepress Kartau et al
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diagnosis was approximately 51 months (Tysabri Safety
Update 09/2019, Biogen data on ﬁle). The mortality rate in
NTZ-PML is 12–24%.63,64
Major risk factors for NTZ-PML are the presence of
serum antibodies to JCPyV, history of prior immunosup-
pression, and a length of NTZ treatment greater than 2
years. A recently acknowledged risk factor is a patient age
over 50 years.65 In elderly patients, risk of lymphopenia is
higher because of age-related immunosenescence, charac-
terized by lower levels and functionality of lymphocytes.
Lower anti-JCPyV antibody levels, or index values, are
associated with lower PML risk in patients without pre-
vious immunosuppressant treatment group.66 For anti-
JCPyV antibody-negative patients, estimated PML risk is
less than 0.07 per 1000 patients. The PML risk is small at
antibody index values of 0.9 or less, and increases with
index values greater than 1.5 in people treated with NTZ
for more than 2 years. The cumulative risk of PML begins
to increase after two years of treatment and the increase
remains constant from year three to year six. In anti-
JCPyV antibody-positive patients, the risk of PML over 6
years is 2.7% in patients with previous immunosuppres-
sant use and 1.7% in those without.66
Adjusted odds ratios of PML associated with DMTs in
2015–2017 were reported as follows: NTZ 115.72, ﬁngo-
limod 4.98, RTX 3.22 and DMF 1.77.67 There is
a potential risk of PML with ocrelizumab use.68 There
are seven carry-over cases of PML with ocrelizumab and
ﬁve reports suggestive of carry-over PML, though not
Table 2 Drugs Associated with PML
Treatment Drugs
Chemotherapeutic
drugs
Alkylating
agents
Camstine,
Cyclophosphamide,
Dacarbazine
Antimetabolites Azathioprine, Cladribine,
Fludarabine, Methotrexate,
Nelarabine
Antitumor
antibiotics
Mitoxantrone
Kinase
inhibitors
Ibrutinib, Pazopanib,
Ponatinib
Other
antineoplastic
agents
Idelalisib
Plant alkaloids Vincristine
Immunosuppressants Belatacept, Cyclosporine,
Cydosporin, Leﬂunomide,
Mycophenolate mofetil,
Sirolimus, Tacrolimus,
Tocilizumab
Oral glucocorticoids All
mAbs for autoimmune diseases and
malignancies
Abatacept, Adalimumab,
Alemtuzumab, Basiliximab,
Belimumab, Bevacizumab,
Brentuximab, Cetuximab,
Denosumab, Eculizumab,
Efalizumab, Etanercept,
Golimumab, Ibritumomab
tiuxetan, Inﬂiximab,
Muromonab-CD3,
Nivolumab, Obinutuzumab,
Ofatumumab,
Pembrolizumab, Rituximab,
Trastuzumab
DMTs for MS mAbs Alemtuzumab, Natalizumab,
Ocrelizumab
Other disease
modifying drugs
Dimethyl fumarate,
Fingolimod
Table 3 PML Risk Under MS DMTs
DMT Incidence of PML
Natalizumab 4.17/1000 treated patients
Fingolimod 0.069–0.082/1000 treated patients
Dimethyl fumarate 0.018/1000 treated patients
Alemtuzumab Low
1 case after second cycle of alemtuzumab
3 suspected cases (EMA database)
1 case with pre-exposure to NTZ
Cladribine Uncertain
Few cases, years after treated of
hematological condition
Ocrelizumab Low
8 cases: 6 in patients with pre-exposure to
NTZ
1 with ﬁngolimod
1 case without previous DMT use
Teriﬂunomide Low
1 case with pre-exposure to NTZ
Interferon-βs Low
1 case of patient with common variable
immunodeﬁciency as a predisposing factor
Glatiramer acetate To date there are no reports of PML
Kartau et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Degenerative Neurological and Neuromuscular Disease 2019:9114
 
D
eg
en
er
at
ive
 N
eu
ro
lo
gi
ca
l a
nd
 N
eu
ro
m
us
cu
la
r D
ise
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
21
4.
14
4.
14
9 
on
 1
1-
Ja
n-
20
20
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
meeting AAN diagnostic criteria.56,69 All ﬁve cases had
MRI ﬁndings compatible with PML. In addition
a confounded case of ocrelizumab monotherapy associated
PML of 78-year old MS patient is reported.70 The inci-
dence rate of PML with ﬁngolimod is 3.12 per 100,000
patient-years.58 DMF-PML cases are usualy associated
with drug-induced prolonged lymphopenia and age of
⩾50 years.57 However, recently a DMF-PML case of a 39-
year patient without repeated lymphocyte counts below
800 cells/μL was reported.71 One case of MS patient`s
PML has been described reported in association with
alemtuzumab.59 Several PML cases have been described
in lymphoma patients receiving polychemotherapy includ-
ing alemtuzumab, but lymphoma is a PML risk factor
itself as well.57 A few PML cases have been described in
patients treated intravenously with cladribine,72 but there
have been no cases of PML with oral cladribine.
Diagnosis of PML
According to the consensus statement from the American
Academy of Neurology, PML diagnosis requires clinical, ima-
ging, and virological evidence to make a deﬁnite, probable, or
possible PML diagnosis.73 The highest level of diagnostic
certainty requires histopathologic conﬁrmation, though this is
a highly invasive procedure. Therefore, the presence of clinical
and/or imaging ﬁndings in combination with JCPyV DNA in
CSF is also considered diagnostic but in the most challenging
cases, brain biopsy may be performed. Brain biopsy has sensi-
tivity of 64–96% and speciﬁcity of 100% in PML.74
PML Clinical Features
The clinical presentation of PML is heterogeneous. The
symptoms result from brain lesions in corresponding
areas.75 Clinical symptoms are not mandatory in the diag-
nosis of conﬁrmed PML, because the disease may be
asymptomatic at the beginning.76 Hemiparesis, ataxia,
gait disturbance, visual deﬁcits, and cognitive changes
are prevalent with limb weakness being the most common
in HIV- and MS-associated PML.75,77 Although rare, brain
stem involvement causes the most severe symptoms. The
disease is progressive and symptoms worsen over time.
There is subtle variation in the presentation of PML as
determined by the underlying cause. In HIV-PML,
50–73% of the patients have predominant motor system
ﬁndings, following cognitive and speech difﬁculties.26,78
In a recent German study of 142 NTZ-PML patients,
33.8% had cognitive and equally as many had motor
symptoms, 26.8% had gait ataxia, 25.3% had speech and
language problems, and 16.2% had vision deﬁcits. 7.7%
were asymptomatic.79 Seizures may occur in up to one-
third of the general PML population and are more frequent
with juxtacortical and T1-hyperintense lesions on MRI.21
Brain Imaging
Brain MRI imaging is the most important diagnostic tool for
PML diagnosis. Frequent brain scans are recommended for
early detection of PML in high-risk patients (those who have
three risk factors for NTZ-PML and those who have not had
immunosuppressant therapy, but have high serum anti-JCPyV
ab index and more than two years of NTZ), because PML
lesions in MRI can develop before clinical symptoms.80,81
The typical imaging features of PML include predilection
for the frontal and parieto-occipital regions and subcortical
location involving U-ﬁbers. Involvement of the overlying
cortex has been increasingly reported.82 Corpus callosum83
or deep grey matter may be affected. Posterior fossa involve-
ment has been reported, most commonly involving the cere-
bellum and middle cerebellar peduncles.84 Lesions have
sharp borders toward gray matter contrasting with ill-
deﬁned borders toward white matter, and increased signal
intensity on T2-weighted and diffusion-weighted images
(DWI).85 T2-weighted imaging may demonstrate
a microcyst or granular pattern.82 On T1-weighted images
PML lesions are hypointense and well-deﬁned, even if small
in size. Usually there is no gadolinium enhancement onMRI,
but 15% of HIV-PML, and 40% of NTZ-PML patients may
exhibit hazy peripheral, sometimes punctate or nodular
enhancement.73 Two types of inﬂammation have been
reported in PML: fatal IRIS type and anti-JCPyV immunor-
eaction type. The latter is associated with good prognosis.86
When mass effect and enhancement are prominent, one
should suspect PML-IRIS, particularly when accompanied
by clinical deterioration. Enhancement at the time of diag-
nosis correlates with decreased survival and greater clin-
ical disability compared to those that do not enhance.87
In NTZ-PML, imaging features can be associated with
prognosis. Radiologically widespread disease at diagnosis
is present in 71% of fatal cases. Asymptomatic cases of
PML found on screening MRI have been associated with
good clinical outcomes.5,88
Laboratory Diagnostics
Detecting JCPyV DNA in CSF by highly sensitive PCR has
great diagnostic value. With new ultrasensitive PCR techni-
ques, the sensitivity is >95% and speciﬁcity is >97%.89
Despite the high sensitivity of PCR, a negative test result
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does not rule out PML,73 because viral loads can be very low
(below 100 copies/mL), while most commercial tests are able
to detect JCPyVDNA in excess of 200 copies/mL.90 In HIV-
infected patients, the viral load in CSF is high and sufﬁcient
for diagnosis. HAART decreases viral load and makes
laboratory-conﬁrmed diagnosis difﬁcult. In patients with
MS or other autoimmune diseases, the viral loads are also
low.73 This creates a need to take multiple CSF samples
despite a clinically strong suspicion of PML due to initial
samples being falsely negative.
Management and Surveillance of PML
There is neither a speciﬁc prophylaxis nor an effective
anti-JCPyV treatment for PML. A number of drugs such
as cytarabine, cidofovir, INF-alpha, meﬂoquine, mirtaza-
pine, and topotecan were used in clinical trials without
beneﬁt.91,92 Currently the approach to treating PML is
prompt immune reconstitution without causing IRIS.
In NTZ-PML patients, immune reconstitution is achieved
by plasma exchange in order to remove NTZ from peripheral
circulation.93 There is one study reporting the beneﬁts of
ﬁlgrastim (granulocyte-colony stimulating factor) in patients
with NTZ-PML.94 In HIV-infected patients, optimization of
HAART is the best therapeutic choice.34
In a portion of the PML population, such as patients
with hematological malignancies, immune reconstitution
cannot be achieved. For these patients, blocking of path-
ways involving programmed cell death 1 (PD-1), a T-cell
surface receptor that keeps the immune system from
attacking the body’s own tissues, and its ligand is a new
promising treatment option. Pembrolizumab and nivolu-
mab, mAbs that both target PD-1, both seem to reduce
JCPy viral load and enhance JCPyV speciﬁc cell mediated
immune responses by preserving and activating CD4+ and
CD8+ cells.95,96 Immune checkpoint inhibitors activate the
immune system, and as a side effect they may exacerbate
any underlying autoimmune disease. A controlled trial is
needed to determine whether PD-1 inhibitors are indeed
able to suppress JCPyV in PML patients, and which sub-
groups would beneﬁt from the treatment. Recently, several
new treatment methods, such as systemic cytokine admin-
istration (interferon-alpha, interleukin-2, and interleukin-7)
and immunization by recombinant human anti-JCPyV VP1
mAbs, JCPyV-speciﬁc cytotoxic T lymphocyte therapy,
cryopreserved BK virus–speciﬁc T cells, and JCPyV cap-
sid protein conjugated with interleukin-7 for PML were
reported.91,97,98
The prognosis of PML has evolved over time, and pro-
longed survival rates are becoming more common in HIV-
and NTZ-PML groups. The survival rate in these groups is
currently 70–80%.36,99 A low viral load in the CSF, VP1
loop-speciﬁc polymorphism, a controlled inﬂammation
mediated by CD4- and CD8-positive T cells, and plasma
cells and a regulatory immune system are associated with
good PML prognosis.13 Predictors of favorable outcomes in
NTZ-PML cases are younger age, lower Expanded
Disability Status Scale score prior to diagnosis, shorter diag-
nostic delay, and more localized brain lesions on MRI at the
time of diagnosis.100 PML cases related to HSCT have
longer time to diagnosis, better survival rates, and lower
mortality rates compared to the cases associated with biolo-
gical treatments or purine analogues.30
In HIV-PML, complete recovery is not to be expected
but one third of the patients may become healthy enough
to have no functional disability. Patients with cerebellar
lesions have a worse outcome due to gait ataxia and
incoordination that precludes independent living.102 Of
NTZ-PML survivors, 40% have severe, 47% moderate,
and 13% mild disability.101
PML-IRIS
In patients with a reversible cause of immunosuppression,
re-establishment of immunocompetence may lead to an
excessively overreactive immune response referred to as
IRIS. The likelihood of developing PML-IRIS depends on
the underlying disease. Approximately 20% of HIV-PML
patients and most NTZ-PML patients treated with immu-
noadsorption develop IRIS.102
IRIS is treatedwith corticosteroids, which have a profound
impact on the virus-speciﬁc T-cell response, especially on
JCPyV. Therefore, they should not be given before the onset
of clinical or radiological signs of IRIS.103 Sometimes pro-
longed corticosteroid therapy102 and treatment with mara-
viroc, a CCR5 receptor antagonist, has been reported and
may be warranted to prevent overshooting damage by
IRIS.104 The observation is not yet conﬁrmed in a large study.
PML-IRIS is a potentially disabling and fatal condition
with a mortality rate of 28%. Fatal PML-IRIS is charac-
terized by excessive cytotoxic CD8-positive T-cell inﬁltra-
tion in the brain. In PML with controlled inﬂammation,
both T- and B-cell lineages appear cooperatively.105
However, several studies have not been able to demon-
strate signiﬁcant differences in survival rates between
PML with and without IRIS.106
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PML Prevention Strategies for MS
Patients
The optimal PML mitigation strategy is prevention and
appropriate surveillance. PML is associated with several
drugs, but so far, a risk stratiﬁcation algorithm has only
been established for NTZ (Table 3). Prior to starting NTZ,
patients must be risk-stratiﬁed for the presence of serum
JCPyV antibodies. Antibody testing is recommended for all
NTZ-treated JCPyV antibody negative patients every six
months, and in the event of seroconversion their therapy
should be changed. MRI screening every 3–4 months is
recommended for patients who receive NTZ for ≥18 months
while JCPyV seropositive. A yearly brain MRI is recom-
mended for patients at low risk of PML (JCPyV seronega-
tive). MRI screening every 3–4 months up to 12 months is
suggested when switching from NTZ to ﬁngolimod, DMF or
alemtuzumab.80 In a recent study by Ryerson et al, for anti-
JCPyVantibody-positiveMS patients, extended interval dos-
ing of NTZ was associated with signiﬁcantly lower PML risk
than standard interval dosing.107
The European Medicines Agency (EMA) recommends
that a complete blood count should be performed before
starting treatment with DMF, and every 3 months during
treatment. A baseline brain MRI should be available as
a reference. If during treatment the lymphocyte counts
drop to low levels for more than 6 months, the doctor
should consider discontinuation of DMF.107 Similar EMA
guidelines exist for ﬁngolimod. Before introducing ﬁngo-
limod treatment, a baseline MRI scan should be available
as a reference. If PML is suspected, MRI should be per-
formed immediately and treatment with ﬁngolimod should
be suspended until PML has been excluded.109
Long-term safety risks of sequential multiple therapies
are still unknown. Currently, succession of therapies for
patients with relapsing-remitting MS is determined by
disease activity, patient-, and drug-related factors. The
risk–beneﬁt ratio of DMTs should be regularly re-
evaluated as it changes with duration of therapy.
Neurologists must remain vigilant for signs and symptoms
of PML when switching from MS therapies associated
with PML to a new MS therapy. PML should be carefully
excluded by clinical-, imaging, and CSF exams, especially
when switching from NTZ or ﬁngolimod to long-lasting
B-cell depleting therapy.
Safety protocols for PML exist for the treatment of MS
patients. Other patients, such as cancer and rheumatic
patients, currently have no such protocols in place.
Conclusion
Many different subgroups of PML, based on the under-
lying diseases have been identiﬁed. These subgroups of
PML have different incidences and prevalences, as well as
different clinical courses and prognoses. While often asso-
ciated with a bad prognosis, in some cases PML may
become inactive, leaving patients with permanent neuro-
logical deﬁcits. The mainstay of PML treatment is immune
reconstitution including discontinuation of the inciting
agent, and with some medications plasma exchange,
although blocking of PD-1 and its ligand, as well as direct
antiviral therapeutics are an active area of investigation.
Diagnosis is challenging and may need repeated clinical
judgement, CSF testing, and MRI.
There is no systematic national or international record
of PML diagnoses, and no risk stratiﬁcation algorithm
except for NTZ. The long-term risk of multiple successive
immunomodulatory and immunosuppressive therapies is
unknown. Global database and recording systems were
developed by the company producing NTZ in order to
follow up the emergence of PML and other adverse events
during NTZ treatment. Surveillance registries as well as
analysis of real-world data to improve the assessment of
PML risk and to tailor prevention strategies for other PML
subgroups are urgently required as well. In addition to
neurologists, physicians from other ﬁelds must be aware
of PML risk associated with mAb and other drugs. Current
information concerning drugs causing PML is mostly pro-
vided by pharmaceutical companies. Large nationwide
studies on the incidence and prevalence of PML with
respect to the underlying diseases and treatments would
provide evidence that is more conclusive.
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